http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
제어기 공용화를 위한 LED 헤드램프 제어용 플랫폼 통합제어기 개발
박충섭(Choongseob Park),박동서(Dongseo Park),이은정(Eunjung Lee),김대현(Daehyun Kim),손유진(Yoojin Son),최윤석(Yunsuk Choi4),박상현(Sanghyun Park),문주환(Juwhan Moon),노태선(Taesun Rho),강소정(Sojeong Kang),이동주(Dongju Lee),김영수(You 한국자동차공학회 2018 한국자동차공학회 부문종합 학술대회 Vol.2018 No.6
For the LED front lamp system, Universal Controller is gradually getting expanded in the world. For corresponding the technical trend and system optimization, we have approached in terms of vehicle level as well as LED load level. By understanding lamp system architecture and hardware functional distribution, we could make discrete LDMs into Universal LDM based on CAN communication. It enables us to control LED lamp very flexible and scalable with regardless of lamp variation depend on regional and specified option. Additionally, it is very compatible with future technologies such as pixel and matrix control in connection with autonomous driving.
Juwhan Choi,이승룡 대한면역학회 2020 Immune Network Vol.20 No.1
Immune checkpoint inhibitors (ICIs) have been changing the paradigm of cancer treatment. However, immune-related adverse effects (irAEs) have also increased with the exponential increase in the use of ICIs. ICIs can break up the immunologic homeostasis and reduce T-cell tolerance. Therefore, inhibition of immune checkpoint can lead to the activation of autoreactive T-cells, resulting in various irAEs similar to autoimmune diseases. Gastrointestinal toxicity, endocrine toxicity, and dermatologic toxicity are common side effects. Neurotoxicity, cardiotoxicity, and pulmonary toxicity are relatively rare but can be fatal. ICI-related gastrointestinal toxicity, dermatologic toxicity, and hypophysitis are more common with anti- CTLA-4 agents. ICI-related pulmonary toxicity, thyroid dysfunction, and myasthenia gravis are more common with PD-1/PD-L1 inhibitors. Treatment with systemic steroids is the principal strategy against irAEs. The use of immune-modulatory agents should be considered in case of no response to the steroid therapy. Treatment under the supervision of multidisciplinary specialists is also essential, because the symptoms and treatments of irAEs could involve many organs. Thus, this review focuses on the mechanism, clinical presentation, incidence, and treatment of various irAEs.
Usefulness of adjuvant chemotherapy in Stage IB NSCLC with high risk factor
( Juwhan Choi ),( Jee Youn Oh ),( Young Seok Lee ),( Kyung Hoon Min ),( Jae Jeong Shim ),( Sue In Choi ),( Dong Won Park ),( Chan Kwon Park ),( Eun Joo Kang ),( Hwan Seok Yong ),( Bong Kyung Shin ),( 대한결핵 및 호흡기학회 2019 대한결핵 및 호흡기학회 추계학술대회 초록집 Vol.127 No.-
Purpose: The efficacy of adjuvant chemotherapy in stage IB non-small-cell lung cancer (NSCLC) with high-risk factors remains unclear and is the focus of our study. Methods: This was a retrospective multi-center study of four academic hospitals. We analyzed 285 stage IB NSCLC patients with high-risk factors according to the 8th edition TNM classification. High-risk factors were visceral pleural invasion, vascular invasion, lymphatic invasion, lung neuroendocrine tumors, and micropapillary histology pattern. We used a Kaplan-Meier survival curve and Cox proportional hazards model to analyze recurrence- free survival and overall survival. Results: Of the 285 cases, 127 (44.6%) were in the adjuvant chemotherapy group and 158 (55.4%) were in the non-adjuvant chemotherapy group (control group). Mean follow-up was 40.2 ± 18.1 months, and median follow-up was 41.5 months. Adjuvant chemotherapy significantly reduced the recurrence risk compared to the control group (Hazards ratio, 0.362; 95% Confidence interval, 0.195-0.672; P = 0.001) and the risk of death compared to the control group (Hazards ratio, 0.155; 95% Confidence interval, 0.050-0.478; P = 0.001). A higher risk of recurrence was found with a larger tumor size and a greater number of risk factors (P = 0.012, P < 0.001, respectively). The risk of death increased when vascular invasion, smoking, or multiple risk factors were present (P = 0.043, P < 0.001, P = 0.048, respectively). Conclusion: Adjuvant chemotherapy may be useful for patients with stage IB NSCLC with high-risk factors and more relevant for patients with larger tumors and multiple risk factors.
( Juwhan Choi ),( Sung Yong Lee ),( Zepa Yang ),( Jinhwan Lee ),( Jun Hee Lee ),( Hyun Koo Kim ),( Hwan Seok Yong ) 대한결핵 및 호흡기학회 2021 대한결핵 및 호흡기학회 추계학술대회 초록집 Vol.129 No.-
Purpose The usefulness of pulmonary rehabilitation in patients with reduced lung function before lung surgery remains unclear, and there is no adequate method for evaluating the effect of rehabilitation. We aimed to evaluate the usefulness of rehabilitation in patients with non-small cell lung cancer (NSCLC) undergoing lung cancer surgery. Materials and Materials and Methods We retrospectively analyzed the medical records of patients with NSCLC who underwent lung surgery at Korea University Guro Hospital between 2018 and 2020. Patients were divided into two groups depending on whether they underwent pulmonary rehabilitation. Pulmonary function test (PFT) data and muscle index determined using chest computed tomography (CT) images were analyzed. Because the baseline characteristics were different between the two groups, propensity score matching was performed. Results Of 325 patients, 75 (23.1%) and 250 (76.9%) were included in the rehabilitation and non-rehabilitation (control) groups, respectively. The rehabilitation group had a worse general condition at baseline. After propensity score matching, 45 patients remained in each group. Pulmonary function (forced expiratory volume in 1 s, %) (P = 0.001) and the muscle index (P = 0.001) were better preserved in the rehabilitation group. Muscle loss of 3.4% and 0.6% was observed in the control and rehabilitation groups, respectively (P = 0.003). In addition, the incidence of embolic events was low in the rehabilitation group (P = 0.044). Conclusion Pulmonary rehabilitation is useful in patients with NSCLC undergoing lung surgery. Pulmonary rehabilitation preserves lung function, muscle and reduces embolic events after surgery. Pulmonary rehabilitation is recommended for patients with NSCLC undergoing surgery.
( Juwhan Choi ),( Jee Youn Oh ),( Young Seok Lee ),( Kyung Hoon Min ),( Jae Jeong Shim ),( Sue In Choi ),( Dong Won Park ),( Chan Kwon Park ),( Eun Joo Kang ),( Hwan Seok Yong ),( Bong Kyung Shin ),( 대한내과학회 2022 The Korean Journal of Internal Medicine Vol.37 No.1
Background/Aims: Adjuvant chemotherapy is the standard of care for resected stage II-IIIA non-small cell lung cancer (NCSLC). The efficacy of adjuvant chemotherapy in stage IB (< 4 cm) NSCLC with high-risk factors is controversial. Methods: This retrospective multicenter study included 285 stage IB NSCLC patients with high-risk factors according to the 8th edition tumor, node, metastasis (TNM) classification from four academic hospitals. High-risk factors included visceral pleural invasion, vascular invasion, lymphatic invasion, lung neuroendocrine tumors, and micropapillary histology patterns. Results: Of the 285 patients, 127 (44.6%) were included in the adjuvant chemotherapy group and 158 (55.4%) were included in the non-adjuvant chemotherapy group. The median follow-up was 41.5 months. Patients in the adjuvant chemotherapy group had a significantly reduced recurrence rate and risk of mortality than those in the non-adjuvant chemotherapy group (hazards ratio, 0.408; 95% confidence interval, 0.221 to 0.754; p = 0.004 and hazards ratio, 0.176; 95% confidence interval, 0.057 to 0.546; p = 0.003, respectively). Adjuvant chemotherapy should be particularly considered for the high-risk factors such as visceral pleural involvement or vascular invasion. Based on the subgroup analysis, adjuvant chemotherapy should be considered when visceral pleural involvement is present, even if the tumor size is < 3 cm. Conclusions: Adjuvant chemotherapy may be useful for patients with stage IB NSCLC with high-risk factors and is more relevant for patients with visceral pleural involvement or vascular invasion.
Choi, Jong Hyun,Choi, Juwhan,Chung, Sang Mi,Oh, Jee Youn,Lee, Young Seok,Min, Kyung Hoon,Hur, Gyu Young,Shim, Jae Jeong,Kang, Kyung Ho,Lee, Hyun Kyung,Lee, Sung Yong The Korean Academy of Tuberculosis and Respiratory 2019 Tuberculosis and Respiratory Diseases Vol.82 No.3
Background: Docetaxel is one of the standard treatments for advanced non-small cell lung cancer. Docetaxel is usually administered in a 3-week schedule, but there is significant toxicity. In this phase II clinical study, we investigated the efficacy and safety of a 4-weekly schedule of docetaxel monotherapy, as first-line chemotherapy for advanced squamous cell carcinoma in elderly lung cancer patients. Methods: Patients with stage IIIB/ IV lung squamous-cell carcinoma age 70 or older, that had not undergone cytotoxic chemotherapy were enrolled. Patients received docetaxel $25mg/m^2$ on days 1, 8, and 15, every 4 weeks. Primary endpoint was the objective response rate (ORR). Secondary endpoints were progression-free survival (PFS), overall survival (OS), and toxicity profiles. Results: A total of 19 patients were enrolled. Among 19 patients, 17 were for evaluated efficacy and safety. In the intent-to-treat population, ORR and disease control rate (DCR) were 11.8% and 47.1%, respectively. In the response evaluable population, ORR was 16.7% and DCR was 66.7%. Median PFS and OS were 3.1 months and 3.3 months, respectively. There were three adverse grade 3/4 events. Grade 1 neutropenia was reported in one patient. Conclusion: Our data failed to demonstrate efficacy of a 4-weekly docetaxel regimen, in elderly patients with a poor performance status. However, incidence of side effects, including neutropenia, was lower than with a 3-week docetaxel regimen, as previously reported.
( Jong Hyun Choi ),( Juwhan Choi ),( Sang Mi Chung ),( Jee Youn Oh ),( Young Seok Lee ),( Kyung Hoon Min ),( Gyu Young Hur ),( Jae Jeong Shim ),( Kyung Ho Kang ),( Hyun Kyung Lee ),( Sung Yong Lee ) 대한결핵 및 호흡기학회 2019 Tuberculosis and Respiratory Diseases Vol.82 No.3
Background: Docetaxel is one of the standard treatments for advanced non-small cell lung cancer. Docetaxel is usually administered in a 3-week schedule, but there is significant toxicity. In this phase II clinical study, we investigated the efficacy and safety of a 4-weekly schedule of docetaxel monotherapy, as first-line chemotherapy for advanced squamous cell carcinoma in elderly lung cancer patients. Methods: Patients with stage IIIB/ IV lung squamous-cell carcinoma age 70 or older, that had not undergone cytotoxic chemotherapy were enrolled. Patients received docetaxel 25 mg/m<sup>2</sup> on days 1, 8, and 15, every 4 weeks. Primary endpoint was the objective response rate (ORR). Secondary endpoints were progression-free survival (PFS), overall survival (OS), and toxicity profiles. Results: A total of 19 patients were enrolled. Among 19 patients, 17 were for evaluated efficacy and safety. In the intentto- treat population, ORR and disease control rate (DCR) were 11.8% and 47.1%, respectively. In the response evaluable population, ORR was 16.7% and DCR was 66.7%. Median PFS and OS were 3.1 months and 3.3 months, respectively. There were three adverse grade 3/4 events. Grade 1 neutropenia was reported in one patient. Conclusion: Our data failed to demonstrate efficacy of a 4-weekly docetaxel regimen, in elderly patients with a poor performance status. However, incidence of side effects, including neutropenia, was lower than with a 3-week docetaxel regimen, as previously reported.